ArticleEJNMMI research2025
Optimizing [
Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intra-patient comparison of tracer uptake and biodistribution of [Annals of nuclear medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFibroblast activation protein inhibitor (FAPI) is a novel PET tracer that targets various malignant tumors. Although some studies have demonstrated that 68Ga-labeled FAPI PET provides diagnostic images shortly after injection, reports on early-phase imaging using [18F]FAPI-74 are limited. This study evaluated the diagnostic potential of early-phase [18F]FAPI-74 PET/CT imaging.
methodsThe cohort comprised 32 patients who underwent whole-body [18F]FAPI-74 PET/CT at three time points: 10, 30, and 60 min after administration. The uptake of [18F]FAPI-74 in normal organs and tumors at each time point was evaluated and compared using standardized uptake value (SUV). The contrast between tumor and background uptake was assessed using tumor-to-blood ratios (TBRs), calculated as the ratio of tumor SUVmax to blood pool SUVmean.
resultsThe uptake of [18F]FAPI-74 in most organs gradually decreased, except in the mammary gland and nipple. Moreover, uptake due to the excretion increased over time in the gallbladder, and bile duct. Among the 72 lesions identified across patients, the median SUVmax of the tumors remained relatively stable across the time points (5.00, 5.16, and 5.11 at 10, 30, and 60 min, respectively), while the median TBRs gradually increased (1.57, 2.24, and 2.94, respectively). Subgroup analysis revealed a similar pattern of increasing median TBRs in primary tumors (2.76, 3.72, and 4.04, respectively), lymph node metastases and peritoneal dissemination (1.67, 2.47, and 3.58, respectively), and lung metastases (0.99, 1.35, and 1.48, respectively).
conclusionsTBRs were highest at 60 min after administration. However, early-phase imaging was considered useful because of its sufficient diagnostic contrast and low physiological uptake in the biliary system.
trial registrationUMIN Clinical Trials Registry, UMIN000051687. Registered 22 July 2023, https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_his_list.cgi?recptno=R000058594 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.